Rheumatology · Autoimmune Arthritis

Rheumatoid Arthritis

USMLE2PANCE
7

Bets

The facts most likely to be tested

1

Rheumatoid arthritis presents with symmetric polyarthritis involving the proximal interphalangeal (PIP) and metacarpophalangeal (MCP) joints with morning stiffness lasting longer than one hour.

Confidence:
2

The distal interphalangeal (DIP) joints are characteristically spared in rheumatoid arthritis, which helps distinguish it from osteoarthritis.

Confidence:
3

Anti-cyclic citrullinated peptide (anti-CCP) antibodies are the most specific serologic marker for rheumatoid arthritis.

Confidence:
4

Rheumatoid factor (RF) is a sensitive but non-specific marker that forms immune complexes contributing to systemic inflammation.

Confidence:
5

Atlantoaxial subluxation is a life-threatening complication of cervical spine involvement that requires screening before intubation.

Confidence:
6

Methotrexate is the first-line disease-modifying antirheumatic drug (DMARD) for the management of rheumatoid arthritis.

Confidence:
7

Felty syndrome is the classic triad of rheumatoid arthritis, splenomegaly, and neutropenia.

Confidence:

Vignette unlocked

A 45-year-old woman presents with a 4-month history of pain and swelling in her hands. She reports morning stiffness that lasts for approximately 90 minutes before improving. Physical examination reveals bilateral swelling of the MCP and PIP joints with ulnar deviation of the fingers. The DIP joints are spared. Laboratory studies show an elevated erythrocyte sedimentation rate and positive anti-CCP antibodies.

What is the most appropriate initial pharmacologic therapy to prevent joint destruction?

+Reveal answer

Methotrexate

The patient's presentation of symmetric inflammatory arthritis involving MCP/PIP joints with morning stiffness is classic for rheumatoid arthritis, and methotrexate is the gold-standard first-line DMARD.

Mo

Depth

Full handout

High yield triage

Etiology / Epidemiology

Autoimmune inflammatory disease affecting women 30-50 years old. Strong association with HLA-DR4.

Clinical Manifestations

Symmetric polyarthritis of MCP and PIP joints with morning stiffness >60 minutes.

Diagnosis

Anti-cyclic citrullinated peptide (anti-CCP) is the most specific test; Rheumatoid Factor is sensitive.

Treatment

Methotrexate is the first-line DMARD; teratogenic and requires folate supplementation.

Prognosis

Progressive joint destruction leads to permanent deformity; increased risk of cardiovascular disease.

Full handout

Epidemiology & Etiology

RA is a chronic systemic autoimmune disease with a 3:1 female-to-male ratio. Genetic predisposition is linked to the HLA-DR4 allele. Smoking is a major environmental trigger that promotes citrullination of proteins.

Pertinent Anatomy

The disease primarily targets the synovium of diarthrodial joints. It characteristically spares the DIP joints, distinguishing it from osteoarthritis. Cervical spine involvement can lead to atlantoaxial subluxation.

Pathophysiology

T-cell mediated immune response leads to synovial hyperplasia, forming a pannus. This invasive tissue secretes TNF-alpha and IL-1, causing cartilage and bone erosion. Chronic inflammation results in systemic manifestations including vasculitis and anemia of chronic disease.

Clinical Manifestations

Patients present with symmetric swelling of the MCP, PIP, and wrist joints. Classic deformities include boutonniere and swan-neck deformities. Cervical spine instability is a critical red flag requiring caution during intubation. Extra-articular findings include rheumatoid nodules and Sjogren's syndrome.

Diagnosis

The ACR/EULAR criteria are used for classification. Anti-CCP antibodies are the most specific diagnostic marker. Rheumatoid Factor is positive in 70-80% of patients. Radiographs show marginal erosions and periarticular osteopenia.

Treatment

Methotrexate is the gold-standard initial DMARD. Hepatotoxicity and bone marrow suppression require regular monitoring. If inadequate, add biologic DMARDs like TNF-inhibitors. Screen for latent TB before starting biologics.

Prognosis

Early initiation of DMARDs is essential to prevent joint destruction. Patients have a significantly higher mortality rate due to accelerated atherosclerosis. Monitor for Felty syndrome (RA, splenomegaly, neutropenia).

Differential Diagnosis

Osteoarthritis: spares MCP joints, no morning stiffness

Systemic Lupus Erythematosus: non-erosive arthritis, positive ANA

Psoriatic Arthritis: involves DIP joints, dactylitis

Gout: monoarticular, needle-shaped negatively birefringent crystals

Reactive Arthritis: follows infection, asymmetric lower extremity involvement